Literature DB >> 22374980

Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.

Shuai Tang1, Miranda L Moore, Jason M Grayson, Purnima Dubey.   

Abstract

Although androgen ablation therapy is effective in treating primary prostate cancers, a significant number of patients develop incurable castration-resistant disease. Recent studies have suggested a potential synergy between vaccination and androgen ablation, yet the enhanced T-cell function is transient. Using a defined tumor antigen model, UV-8101-RE, we found that concomitant castration significantly increased the frequency and function of antigen-specific CD8(+) T cells early after the immunization of wild-type mice. However, at a late time point after immunization, effector function was reduced to the same level as noncastrated mice and was accompanied by a concomitant amplification in CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) following immunization. We investigated whether Treg expansion occurred following castration of prostate tumor-bearing mice. In the prostate-specific Pten(-/-) mouse model of prostate cancer, we observed an accelerated Treg expansion in mice bearing the castration-resistant endogenous prostate tumor, which prevented effector responses to UV-8101-RE. Treg depletion together with castration elicited a strong CD8(+) T-cell response to UV-8101-RE in Pten(-/-) mice and rescued effector function in castrated and immunized wild-type mice. In addition, Treg expansion in Pten(-/-) mice was prevented by in vivo interleukin (IL)-2 blockade suggesting that increased IL-2 generated by castration and immunization promotes Treg expansion. Our findings therefore suggest that although effector responses are augmented by castration, the concomitant expansion of Tregs is one mechanism responsible for only transient immune potentiation after androgen ablation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374980      PMCID: PMC3690568          DOI: 10.1158/0008-5472.CAN-11-2499

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro.

Authors:  Ludger Klein; Khashayarsha Khazaie; Harald von Boehmer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-11       Impact factor: 11.205

2.  T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

Authors:  M Mercader; B K Bodner; M T Moser; P S Kwon; E S Park; R G Manecke; T M Ellis; E M Wojcik; D Yang; R C Flanigan; W B Waters; W M Kast; E D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

3.  In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.

Authors:  Chao-Lien Liu; Peiqing Ye; Benjamin C Yen; Carol H Miao
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

4.  Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.

Authors:  J A Eastham; L D Truong; E Rogers; M Kattan; K C Flanders; P T Scardino; T C Thompson
Journal:  Lab Invest       Date:  1995-11       Impact factor: 5.662

5.  Castration alters peripheral immune function in normal male mice.

Authors:  S M Viselli; S Stanziale; K Shults; W J Kovacs; N J Olsen
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

6.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

7.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

8.  Expression of transforming growth factor-beta 1 in prostate cancer.

Authors:  M S Steiner; Z Z Zhou; D C Tonb; E R Barrack
Journal:  Endocrinology       Date:  1994-11       Impact factor: 4.736

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  29 in total

Review 1.  DNA vaccines for prostate cancer.

Authors:  Christopher D Zahm; Viswa Teja Colluru; Douglas G McNeel
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

Review 2.  Androgen deprivation and immunotherapy for the treatment of prostate cancer.

Authors:  Melissa Gamat; Douglas G McNeel
Journal:  Endocr Relat Cancer       Date:  2017-08-16       Impact factor: 5.678

Review 3.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

4.  Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.

Authors:  Zhi Qi; Zihan Xu; Liuzhen Zhang; Yongkang Zou; Jinping Li; Wenyu Yan; Cheng Li; Ningshu Liu; Hong Wu
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

5.  Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Authors:  Brian M Olson; Ewa Jankowska-Gan; Jordan T Becker; Dario A A Vignali; William J Burlingham; Douglas G McNeel
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

6.  Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.

Authors:  Luis M Vence; Chiyu Wang; Himabindu Pappu; Ryan E Anson; Tejal A Patel; Priscilla Miller; Roland Bassett; Gregory Lizee; Willem W Overwijk; Krishna Komanduri; Cara Benjamin; Gladys Alvarado; Sapna P Patel; Kevin Kim; Nicholas E Papadopoulos; Agop Y Bedikian; Jade Homsi; Wen-Jen Hwu; Richard Boyd; Laszlo Radvanyi; Patrick Hwu
Journal:  J Immunother       Date:  2013-05       Impact factor: 4.456

7.  CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis.

Authors:  Mohammed S M Almuslehi; Monokesh K Sen; Peter J Shortland; David A Mahns; Jens R Coorssen
Journal:  Front Cell Neurosci       Date:  2020-03-10       Impact factor: 5.505

8.  Regulatory T cells in radiotherapeutic responses.

Authors:  Dörthe Schaue; Michael W Xie; Josephine A Ratikan; William H McBride
Journal:  Front Oncol       Date:  2012-08-17       Impact factor: 6.244

9.  Opposing effects of androgen ablation on immune function in prostate cancer.

Authors:  Shuai Tang; Purnima Dubey
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

Review 10.  Targeting the spectrum of immune checkpoints in prostate cancer.

Authors:  Laura A Sena; Samuel R Denmeade; Emmanuel S Antonarakis
Journal:  Expert Rev Clin Pharmacol       Date:  2021-07-15       Impact factor: 4.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.